Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer
(2018) In Clinical and Translational Radiation Oncology 13. p.24-28- Abstract
Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/11d4f4c9-a26b-4a93-8652-61569e35ab8e
- author
- publishing date
- 2018-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- EBUS, Endoscopic ultrasound, Image-guided radiotherapy, Liquid fiducial marker, NSCLC
- in
- Clinical and Translational Radiation Oncology
- volume
- 13
- pages
- 24 - 28
- publisher
- Elsevier
- external identifiers
-
- scopus:85069701708
- ISSN
- 2405-6308
- DOI
- 10.1016/j.ctro.2018.07.004
- language
- English
- LU publication?
- no
- additional info
- Publisher Copyright: © 2018 The Authors
- id
- 11d4f4c9-a26b-4a93-8652-61569e35ab8e
- date added to LUP
- 2023-07-19 17:13:37
- date last changed
- 2023-07-31 11:12:02
@article{11d4f4c9-a26b-4a93-8652-61569e35ab8e, abstract = {{<p>Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.</p>}}, author = {{de Blanck, Steen Riisgaard and Rydhög, Jonas Scherman and Larsen, Klaus Richter and Clementsen, Paul Frost and Josipovic, Mirjana and Aznar, Marianne Camille and af Rosenschöld, Per Munck and Jølck, Rasmus Irming and Specht, Lena and Andresen, Thomas Lars and Persson, Gitte Fredberg}}, issn = {{2405-6308}}, keywords = {{EBUS; Endoscopic ultrasound; Image-guided radiotherapy; Liquid fiducial marker; NSCLC}}, language = {{eng}}, pages = {{24--28}}, publisher = {{Elsevier}}, series = {{Clinical and Translational Radiation Oncology}}, title = {{Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer}}, url = {{http://dx.doi.org/10.1016/j.ctro.2018.07.004}}, doi = {{10.1016/j.ctro.2018.07.004}}, volume = {{13}}, year = {{2018}}, }